We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+71.22%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$729M
AUM Growth
+$327M
Cap. Flow
+$45.1M
Cap. Flow %
6.18%
Top 10 Hldgs %
57.09%
Holding
84
New
23
Increased
22
Reduced
20
Closed
15

Top Buys

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$40.8M
2
UTHR icon
United Therapeutics
UTHR
+$26.2M
3
HSKA
Heska Corp
HSKA
+$20M
4
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$18.2M
5
AZN icon
AstraZeneca
AZN
+$10.8M

Top Sells

Rank Stock Value
1
CCXI
ChemoCentryx, Inc.
CCXI
+$29.3M
2
ZGNX
Zogenix, Inc.
ZGNX
+$27.8M
3
DHR icon
Danaher
DHR
+$20.4M
4
APLS
Apellis Pharmaceuticals
APLS
+$15.4M
5
GSK icon
GSK
GSK
+$11.6M

Sector Composition

Rank Sector Weight
1 Healthcare 81.4%
2 Miscellaneous 16.98%
3 Communication Services 1.62%
4 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MGNX icon
76
MacroGenics
MGNX
$263M
– –
-91,998
Closed -$535K
NVST icon
77
Envista
NVST
$4.36B
– –
-109,212
Closed -$1.63M
PBYI icon
78
Puma Biotechnology
PBYI
$468M
– –
-58,251
Closed -$492K
XENE icon
79
Xenon Pharmaceuticals
XENE
$5.81B
– –
-71,591
Closed -$812K
AGRX
80
DELISTED
Agile Therapeutics
AGRX
– –
-356
Closed -$1.32M
XLRN
81
DELISTED
Acceleron Pharma
XLRN
– –
-42,305
Closed -$3.8M
KDMN
82
DELISTED
Kadmon Holdings, Inc.
KDMN
– –
-975,350
Closed -$4.09M
GNMK
83
DELISTED
GenMark Diagnostics, Inc
GNMK
– –
-524,257
Closed -$2.16M
PFNX
84
DELISTED
Pfenex Inc.
PFNX
– –
-46,293
Closed -$408K
1 2 3
4

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q2 2020 Portfolio in Review

As of Q2 2020, Eversept Partners held 84 positions worth $729M, up 81% from $402M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Eversept Partners deployed $45.1M of net new capital in Q2 2020, opening 23 new positions and adding to 22 existing holdings. Its largest new stake was Horizon Therapeutics Public Limited Company Ordinary Shares: 954,738 shares worth $53.1M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, down from 92% a quarter earlier, followed by Miscellaneous and Communication Services.

On the sell side, the largest reduction was ChemoCentryx, Inc., an estimated $29.3M trimmed.

  • Eversept Partners's largest Q2 2020 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 954,738 shares worth $53.1M.
  • Eversept Partners added most to Heska Corp in Q2 2020, an estimated $20M increase.
  • Eversept Partners's biggest Q2 2020 reduction was ChemoCentryx, Inc., cutting an estimated $29.3M.
  • Eversept Partners fully exited Kadmon Holdings, Inc. in Q2 2020, selling an estimated $4.09M.
  • Eversept Partners's ten largest holdings make up 57% of its $729M portfolio in Q2 2020.
  • Eversept Partners opened 23 new positions and closed 15 in Q2 2020.
  • Eversept Partners's portfolio value rose 81% quarter-over-quarter to $729M.

Based on Eversept Partners's 13F filing for Q2 2020, filed 13 Aug 2020.